Literature DB >> 24147822

Comparison of patient-controlled analgesia versus continuous infusion of tramadol in post-cesarean section pain management.

Ismail Demirel1, Ayse Belin Ozer, Remzi Atilgan, Burcin Salih Kavak, Serap Unlu, Mustafa Kemal Bayar, Ekrem Sapmaz.   

Abstract

AIM: To evaluate and compare analgesic efficacy, drug consumption and patient satisfaction with the i.v. patient-controlled and continuous infusion modes of administration of tramadol.
METHODS: A total of 40 pregnant women in American Society of Anesthesiologists physical status classification system risk classes I-II scheduled for cesarean section were randomized into two groups to receive treatment in single-blind fashion. Patients in both groups received tramadol as an i.v. infusion 15 min before the end of surgery under general anesthesia for cesarean section. In the post-anesthesia care unit, the 20 patients allocated to group I were given i.v. tramadol in patient-controlled anesthesia (PCA), while the 20 other patients assigned to group II received it as a continuous infusion. Pain visual analog scores (VAS), mean arterial pressure (MAP), heart rate, total tramadol consumption, sedation scores, side-effects (nausea/vomiting) and patient satisfaction were evaluated seven times in the course of the first postoperative 24 h. The Mann-Whitney U-test and Friedman's anova were used for the statistical treatment of data.
RESULTS: VAS, sedation scores and nausea/vomiting scores were similar in both groups (P > 0.05). The 24-h tramadol consumption was significantly lower in group I (420.15 ± 66.58 mg) than in group II (494.00 ± 29.45 mg), while patient satisfaction was significantly higher in group I (P < 0.05).
CONCLUSION: While tramadol administration by either of the methods used may ensure efficient early postoperative anesthesia in cesarean section patients, i.v. PCA may be preferred because of the lower drug consumption and higher patient satisfaction associated with it.
© 2013 The Authors. Journal of Obstetrics and Gynaecology Research © 2013 Japan Society of Obstetrics and Gynecology.

Entities:  

Keywords:  analgesia; cesarean section; infusions; intravenous; patient-controlled; tramadol

Mesh:

Substances:

Year:  2013        PMID: 24147822     DOI: 10.1111/jog.12205

Source DB:  PubMed          Journal:  J Obstet Gynaecol Res        ISSN: 1341-8076            Impact factor:   1.730


  5 in total

1.  Intermittent tramadol vs tramadol administration via patient-controlled pump after lumbar discectomy: a randomized controlled trial.

Authors:  Biljana Kurtović; Krešimir Rotim; Tomislav Sajko; Cecilija Rotim; Adriano Friganović; Milan Milošević
Journal:  Croat Med J       Date:  2022-04-30       Impact factor: 2.415

2.  Comparison of patient-controlled intravenous analgesia with sufentanil versus tramadol in post-cesarean section pain management and lactation after general anesthesia - a prospective, randomized, double-blind, controlled study.

Authors:  Xiaohui Chi; Man Li; Wei Mei; Mingfeng Liao
Journal:  J Pain Res       Date:  2017-07-03       Impact factor: 3.133

3.  Comparison of different sufentanil-tramadol combinations for pain relief within the first 24 hours after cesarean section: a retrospective study.

Authors:  Xueqin Cao; Xianwei Zhang
Journal:  J Pain Res       Date:  2018-10-23       Impact factor: 3.133

4.  Patient-controlled intravenous tramadol versus patient-controlled intravenous hydromorphone for analgesia after secondary cesarean delivery: a randomized controlled trial to compare analgesic, anti-anxiety and anti-depression effects.

Authors:  Guangyou Duan; Xiaohang Bao; Guiying Yang; Jing Peng; Zhuoxi Wu; Peng Zhao; Zhiyi Zuo; Hong Li
Journal:  J Pain Res       Date:  2018-12-18       Impact factor: 3.133

5.  Protocol for a randomised, double-blind, placebo-controlled trial to explore the effect of tramadol in the prevention of postpartum depression (ETPPD).

Authors:  Guangyou Duan; Zhuoxi Wu; Peng Zhao; Jing Peng; Zhengqiong Chen; Qingling Zhang; Rufu Xu; Hong Li
Journal:  BMJ Open       Date:  2018-10-21       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.